Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference
November 10 2020 - 4:30PM
Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a
pharmaceutical technology company, today announced that Robert F.
Apple, President and Chief Executive Officer is scheduled to
present at the Jefferies Virtual London Healthcare Conference.
Details of the presentation are as follows:
Event: |
Jefferies Virtual London Healthcare Conference |
Format: |
Fireside
Chat and 1x1 Meetings |
Fireside
Chat Date: |
Tuesday,
November 17, 2020 |
Fireside
Chat Time: |
1:45pm
ET |
A live webcast of the fireside chat will be
available under the “For Investors” section of the Antares Pharma
website at www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a pharmaceutical
technology company focused primarily on the development and
commercialization of self-administered injectable pharmaceutical
products using advanced drug delivery auto injector technology. The
Company has a portfolio of proprietary and partnered commercial
products with several product candidates in various stages of
development, as well as significant strategic alliances with
industry leading pharmaceutical companies including Teva
Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc.
(AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd.
(Idorsia). Antares Pharma’s FDA-approved products include XYOSTED®
(testosterone enanthate) injection, OTREXUP® (methotrexate)
injection for subcutaneous use and Sumatriptan Injection USP, which
is distributed by Teva. The Company also markets NOCDURNA®
(desmopressin acetate) in the U.S., which was licensed from Ferring
Pharmaceuticals.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe
harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are subject to certain risks and uncertainties that can
cause actual results to differ materially from those described.
Factors that may cause such differences include, but are not
limited to: the Company’s ability to achieve the reinstated 2020
full-year revenue guidance; the uncertainty
regarding the duration, scope and severity of the COVID-19 pandemic
and the mitigation measures and other restrictions implemented in
response to the same and the impact on
demand for our products, new patients and
prescriptions, future revenue, product supply, and
our overall business, operating results and financial
condition; successful commercialization of
NOCDURNA® in the United States
and market acceptance and future revenue from the
same: commercial success of
XYOSTED® and future
revenue from the same; market acceptance of Teva’s
generic epinephrine auto-injector product and future revenue from
the same; whether the FDA will withdraw marketing
approval for AMAG’s Makena®
subcutaneous auto injector following the recent FDA letter
seeking withdrawal, whether AMAG will be granted an appeal hearing
and if granted, whether AMAG will be successful and
future prescriptions, market acceptance
and revenue from the same; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan
Injection USP and the amount of revenue from the same; future
prescriptions and sales of
OTREXUP®; Teva’s ability to
successfully commercialize generic teriparatide in 11 countries in
Europe, Canada and Israel and future revenue from the same,
successful development including the timing and results of the
clinical bridging and Phase 3 clinical trial of the drug device
combination product for Selatogrel
with Idorsia Pharmaceuticals and FDA and global regulatory
approvals and future revenue from the same; FDA approval of Teva’s
pending ANDA for generic Forteo
and future revenue from the same; the timing and results of
the Company’s or its partners’ research projects or clinical trials
of product candidates in development including Pfizer’s undisclosed
development product; actions by the FDA or other regulatory
agencies with respect to the Company’s products or product
candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to meet loan extension and interest only payment milestones and the
ability to repay the debt obligation to Hercules Capital; the
Company’s ability to obtain financial and other resources for its
research, development, clinical, and commercial activities and
other statements regarding matters that are not historical facts,
and involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:Tram BuiVice President,
Corporate Communications and Investor
Relations609-359-3016tbui@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2023 to Sep 2024